Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...

We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.

Johnson & Johnson's stock has seen modest gains in recent months. Read why I downgrade JNJ stock from buy to hold.

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The cost ...

Johnson & Johnson’s (NYSE:JNJ) is the producer of some top-selling drugs which include Stelaera, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, and Opsumit. In the second ...

Johnson & Johnson’s (NYSE:JNJ) top-selling drugs include Stelaera, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, and Opsumit. In the second quarter of 2024, the company ...

Bayer and its development partner for Nubeqa – Finland's Orion Pharma – reckon that their drug may have a safety advantage that will help it wrest market share from Xtandi and Erleada ...

Johnson & Johnson’s (NYSE:JNJ) top-selling drugs include Stelaera, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, and Opsumit. In the second quarter of 2024, the company reported ...